Can expanded use of oncology biosimilar agents and supportive care agents help support the CMS' value-based care efforts?
The authors of a European review provide recommendations for all stakeholders on smooth implementation of cancer biosimilar agents.
A recent study in JAMA Oncology examined the average daily cost of biosimilar filgrastim-sndz compared with the brand name biologic.
Gary H. Lyman, MD, MPH, says the plan does not address several significant concerns, such as delay tactics that limit prompt access to biosimilars.
Various challenges still surround the use of cancer biologics, but expert guidance and expiring patents may help expand their use and benefits.
Research presented this week at ESMO studied the efficacy of biosimilars to trastuzumab compared with the reference product in breast cancer.
The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer.
Last year saw the first two FDA approvals of oncology biosimilars, but experts have voiced concerns about the emerging US biosimilars market, particularly regarding clinical uptake and uncertainty about costs.
The FDA approved a biosimilar for trastuzumab, Ogivri, for the treatment of patients with HER2-positive breast and stomach cancer.
The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.